Full-Time
Updated on 8/7/2026
Blood-based cancer detection via sequencing tests
$82k - $102k/yr
Durham, NC, USA
In Person
On-site full-time; occasional overtime or off-shift support may be required.
Bachelor's
| , |
See people who can refer or advise you
GRAIL develops blood-based cancer tests that aim to detect cancer at its earliest stages. The tests use high-intensity sequencing to analyze large amounts of tumor genome data from a blood sample and apply advanced algorithms and deep learning to identify signals indicating cancer. Revenue comes from selling these tests to healthcare providers and research institutions, with potential expansion to direct-to-consumer sales in the future. Compared with others, GRAIL combines extensive sequencing data with clinical studies and sophisticated analytics to provide actionable cancer-detection results, focusing on early diagnosis. The company’s goal is to lower global cancer mortality by catching the disease early when treatment is more effective.
Company Size
1,001-5,000
Company Stage
Post IPO Equity
Headquarters
Menlo Park, California
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.
GRAIL reported second-quarter revenue of $44.7 million, up 26% year-over-year, driven by higher Galleri test volumes. The company sold more than 61,000 Galleri tests during the quarter, a 35% increase from the prior year. Screening revenue contributed $42.6 million, up 24%, whilst development services revenue totalled $2 million. For the first half of the year, screening revenue exceeded $80 million, up 30%, with test volume surpassing 117,000 tests. GRAIL reported a net loss of $110.2 million, down 3% from the previous year. The company ended the quarter with $861.6 million in cash, including a $110 million investment from Samsung that closed in June. The company has submitted its premarket approval application to the FDA and expects an advisory committee review in autumn.
$GRAL securities: suffer losses on your GRAIL, Inc. investment? BFA Law reminds investors of the Securities Fraud lawsuit to recover losses. A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial, potentially violating federal securities laws. NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit. Key Details of the GRAIL ($GRAL) Class Action: * Lead Plaintiff Deadline: August 4, 2026 * Alleged Misconduct: Securities fraud relating to GRAIL's NHS-Galleri cancer trial * Stock Drop: February 20, 2026 - 50.55% Stock Drop * Court: U.S. District Court for the Northern District of California * Action: Contact BFA Law to discuss your rights Investors have until August 4, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GRAIL common stock. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned Robbins v. GRAIL, Inc., et al., No. 26-cv-05428. Why is GRAIL Being Sued for Securities Fraud? GRAIL is a commercial-stage healthcare company focused on early cancer detection. GRAIL developed Galleri, a multi-cancer early detection test that analyzes blood samples to screen for multiple cancers, identify the likely organ or tissue of origin, and assist in the screening process. As part of GRAIL's efforts to attain an accelerated implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not." According to the complaint, during the relevant period, GRAIL made positive statements about Galleri, the NHS-Galleri trial design, and top-line results from the first screening round, including that the NHS-Galleri trial was "designed with three consecutive years of screening in order to achieve the primary endpoint," and that "Galleri is working in the real world." As alleged, in truth, the NHS-Galleri trial's three-year timeframe was insufficient to demonstrate the primary endpoint. Why did GRAIL's Stock Drop? On February 19, 2026, GRAIL announced top-line results from its NHS-Galleri trial. Although the Company emphasized certain favorable results, GRAIL disclosed that the trial did not meet its primary endpoint. Specifically, GRAIL stated that the "primary endpoint of statistically significant Stage III-IV reduction was not observed." GRAIL attributed the disappointing outcome, in part, to "probably need[ing] a longer follow-up time to be able to [compare the two arms of the study] adequately." This news caused the price of GRAIL stock to decline $51.32 per share, or 50.55%, from a closing price of $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026. What Can You Do? If you invested in GRAIL, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Today in New York do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
News for rocket scientists. GRAIL, Inc. sued for securities Law violations - contact the DJS Law Group to discuss your rights - GRAL. LOS ANGELES, July 31, 2026 /PRNewswire/ - The DJS Law Group reminds investors of a class action lawsuit against GRAIL, Inc. ("Grail" or "the Company") (NASDAQ: GRAL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GRAL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: May 13, 2025 to February 19, 2026 DEADLINE: August 4, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false and materially misleading throughout the class period. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. Really Rocket Science specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Its clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of its clients are extraordinarily valuable assets that demand respect, focus, and results. David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 SOURCE DJS Law Group LLP
GRAIL to present at the Canaccord Genuity 46th Annual Growth Conference. Jul 30, 2026, 16:01 ET MENLO PARK, Calif., July 30, 2026 /PRNewswire/ - GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, Aug. 11 at 10:00 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAIL GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. SOURCE GRAIL, Inc.
INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in GRAIL, Inc. of class action lawsuit and upcoming deadlines - GRAL. Globe Newswire 28-Jul-2026 5:23 PM NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. ("Grail" or the "Company") (NASDAQ:GRAL).??? Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Grail and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 4, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Grail securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.??? On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On this news, Grail's stock price fell more than 50%, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. ?Prior results do not guarantee similar outcomes.???